PDF icon Download PDF
Onkologische Welt 2025; 16(06): 313-319
DOI: 10.1055/a-2665-1695
Kongressnachlese

ICML-Highlights 2025 - Alte Therapiestandards wanken, Chemotherapien auf dem Rückzug

› Further Information
Also available ateRef
   Permissions and Reprints
Preview

Zusammenfassung

Auf der 18. International Conference on Malignant Lymphoma (ICML) gab es für die inzwischen über 4000 Teilnehmer (plus Online-Besucher) angesichts von mehr als 1000 eingereichten Abstracts eine kaum zu bewältigende Fülle von Informationen. Der Kongress wurde aber auch 2025 seinem Ruf als exzellentes Diskussionsforum zwischen hämatoonkologischer Wissenschaft und Praxis gerecht.



Publication History

Article published online:
02 September 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Sancho JM. et al. Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase III POLARGO trial. 2025; Oral Session 007
  • 2 Abramson JS. et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO. . ICML 2025; Oral Session 076
  • 3 Westin J. et al. Mosunetuzumab plus polatuzumab vedotin is superior to R-GemOx in transplant-ineligible patients with R/R LBCL: primary results of the Phase III SUNMO trial. ICML 2025; Oral Session LBA3
  • 4 Wurm-Kuczera R. et al. R-Pola-Glo – Chemo-light Frontline Therapy Induces High Response Rates with a favorable Safety Profile in Elderly/Frail Patients with Aggressive Lymphoma. ICML 2025; Abstract 159
  • 5 Belada D. et al. EPCORE DLBCL-3: Fixed-Duration Epcoritamab Monotherapy in older (≥ 75 Y), Anthercycline-inegligible Patients with previously untreated Large B-Cell Lymphoma (LBCL). ICML 2025; Abstract 158
  • 6 Thiruvengadam SK. et al. Outcomes of Glofitamab and Epcoritamab in R/R DLBCL elderly patients: A Real-World Evidence Study from the CUBIC Consortium. ICML 2025; Abstract 161
  • 7 Falchi L. et al. Mosunetuzumab (mosun) Produces Durable Benefit in Patients (pts) with Newly Diagnosed Follicular Lymphoma (FL): Extended Follow up of the MITHIC-FL1 Trial. ICML 2025; Oral Session 027
  • 8 Budde LE. et al. Fixed duration subcutaneous Mosunetuzumab in patients with previously untreated high tumor burden follicular lymphoma: interim results from the Phase II MorningSun study. ICML 2025; Oral Session 099
  • 9 Sehn L. et al. Outcomes From the Phase 3 inMIND Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and Rituximab (R) for Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL). ICML 2025; Oral Session 028
  • 10 Thieblemont C. et al. Phase 2 ELARA Trial 4-year Update: Clinical Outcomes of Tisagenlecleucel in Patients (pts) With High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL). ICML 2025; Oral Session 138
  • 11 Russler-Germain D. et al. Large B-cell Lymphoma Microenvironment Archetype Profiles (LymphoMAPs) identify subgroups with greatest benefit from CD19 CAR T-cell therapy. ICML 2025; Abstract 005
  • 12 Johnston PB. et al. Tandem CD20–19-Directed Non-Cryopreserved CAR-T Cells– Zamtocabtagene Autoleucel (Zamto-cel) – in Patients with Relapsed/Refractory CNS Lymphoma in DALY II US study. ICML 2025; Oral Session 089
  • 13 Shaw NN. et al. Interim Results of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells – Zamtocabtagene Autoleucel in Relapsed/Refractory Diffuse Large B Cell Lymphoma. ICML 2025; Oral Session 105
  • 14 Kuipers MT. et al. High CR and MRD Negativity Rates With GLPG5101, a Fresh, Stem-Like, Early Memory CD19 CAR T With 7-Day Vein-to-Vein Time: Full Results From ATALANTA-1 Cohort 3 (iNHL). ICML 2025; Oral Session 102